Fresh analysis suggests that individuals who discontinue popular weight-loss injections like Mounjaro or Wegovy can put back on reduced body mass much more quickly than those who end conventional diet and exercise plans.
Research printed in a leading health publication shows that while overweight people often shed substantial amounts of their body weight while using the jabs, the weight returns at an average rate of nearly a kilo each month upon discontinuation.
"Users purchasing these treatments must be informed of the risk of rapid rebound weight gain when the therapy is stopped," cautioned expert Dr. Susan Jebb.
This pace of regain implies a return to original weight within about 18 months.
Comparing Approaches
The research, which examined 37 of trials involving over 9,000 of patients, contrasted the outcomes of these new drugs with conventional dieting.
Researchers note that individuals who lose weight through dieting generally experience a more gradual creep back—approximately 100 grams monthly—after stopping.
Understanding the Quick Regain
Doctors suggest the mechanism of the jabs accounts for the accelerated rebound.
The injections mimic a natural hormone called GLP-1, which moderates hunger.
"Sustained high doses of GLP-1 levels far above than normal could lead to the system to produce less of its own natural GLP-1, and may also diminish sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' results in appetite is no longer kept in check, making binge eating a significant risk."
A Lifelong Issue?
The NHS suggest the injections for individuals with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
Professionals argue that, due to the significant potential of relapse, the treatment should be considered life-long.
This perspective is supported by drug manufacturers, who note that the results "underscore the persistent nature of excess weight," comparing it to managing diseases like diabetes.
Patient Experiences
Individuals who have discontinued the jabs report a powerful resurgence of appetite.
"It was like something that goes on and you become extremely hungry," recalled an individual.
The struggle is compounded if users have not adopted sustainable dietary or behavioural changes during treatment.
Widespread Adoption
Recent estimates suggest that millions of people in the UK have tried weight-loss jabs in the past year, with interest being substantial.
- Use is higher among females compared to men.
- The middle-aged age group shows the highest usage rates.
- A large proportion obtain the medications through private healthcare rather than public health services.
In conclusion, researchers emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a permanent cure and lasting health benefits hinges on integrated behavioural changes.
